Oncolytics Biotech Inc T.ONC

Panc Biomarker Presentation at ASCO GI 18-20 Jan 2024

[askretka]

https://delta.larvol.com/Products/?ProductId=f7cc900b-0f3a-4b2e-b388-a7405966dd86

Cheers!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

[pelaboost]

@askretka. If Andrus Reo is involved, it should be  noted that Andrus is a Russian biotech that was at least in part funded by a Russian government biotech fund. Between Andrus, Anson and no abstract one can one can only surmise that this is getting curiouser and curiouser.

[pelaboost]

@askretka. It now appears that there is a second poster - Anne Noonan - CEACAM6 and IFITM3 as potential biomarkers. Those are the same potential biomarkers in your first post Would you please confirm that there are now 2 posters both with the same potential biomarkers. TIA

[Noteable]

Repost:      

[Noteable]

Stockhouse is now garbbling reposted messages, which means that someone wants subject the followers to further manipulation of the ONCY message boards. Wat too bad. 

[Noteable]

Should read: " ...... someone wants to subject the followers to further manipulation of the ONCY message boards .."

[askretka]

No I think it's the same one.  Jon Hays got the Research award for it, but looks like he was working with Anne Noonan and others at Ohio State University.  Anne Noonan The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital info_outline Anne Noonan, Jason David, John Hays, James Chen

[Journeytc]

I didn't know there was a marker for panc?  Did they use it in trial?   I don't think so?   Panc numbers were pretty high so not sure how this helps. 

[Noteable]

Oncolytics Biotech® Announces Clinical & Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer - May 2021 The GOBLET (Gastrointestinal tumOrs exploring the treatment comBinations with the oncolytic reovirus peLarEorep and anTi-PD-L1) study is a phase 1/2 multiple indication biomarker, safety, and efficacy study in

[Journeytc]

Thankyou

[13X2413]

I may be wrong, but it looks like regurgitated old news Noteable posted. Hard to get excited   

[Noteable]

The information that I posted was presented to counter those who tried to deny that biomarkers were involved in ONCY's Phase 1/2  Goblet GI / pancreatic cancer study, notwithstanding what others are trying to spin.

[Noteable]

Biomarkers serve to facilitate the granting of an Accelerated Approval, as the FDA continues towards advancing precision medicine.

[Noteable]

Surrogate Endpoints Surrogate endpoints are often called biomarkers or surrogates. Surrogate endpoints are validated measures backed by science. Surrogate endpoints measure outcomes that are reasonably likely to predict clinical benefit. Allow for shorter clinical trials and earlier access to treatments when, in many cases, a clinical outcome such

[fox7mf]

A poster on Stocktwits just posted that Oncy's San Diego location is on the market...available for lease immediately. Interesting. Happy New Year all.

[13X2413]

Here's the listing..... Here's the listing...... 8th Floor, Ste 850 8th Floor, Ste 850 8th Floor, Ste 850 SIZE 3,882 SF TERM Negotiable RENTAL RATE $60.47 CAD/SF/YR SPACE USE Office CONDITION - AVAILABLE 2024-02-01  

[13X2413]

Sorry if the message wasn't formatted properly. Tried to copy and paste. 

[Noteable]

ONCY US Office 4660 La Jolla Village Dr. Suite 850 San Diego, CA 9212 https://oncolyticsbiotech.com/contact/ La Jolla Center 4660 La Jolla Village Dr ALL AVAILABLE SPACES(8) Display Rental Rate as $/SF/YR SPACE SIZE TERM RENTAL RATE SPACE USE

[Noteable]

https://www.griproom.com/fun/10-signs-your-company-is-about-to-be-acquired Relevant points 8.9.& 10. 

[itntdf]

If they’re a high-level insider, they probably own stock in the company. Check out the insider transactions. If they held their stock, but left the company…that can be a major tell. believe andrew exercised his options, bought but did not sell.

[lonc17]

It is impossible to know whether or not Anderw dG has sold his shares.  If his last day of employment was sometime around December 5th, then he might have sold all of his shares as early as December 1st and would never have had to report to SEDI, as he was no longer an insider after the 5 day grace period for reporting.  Stilll wondering what happened to him. 

[13X2413]

Any connection to their San Diego office space up for lease?

[13X2413]

Yep. It's available Feb 1. 

[inthno]

https://www.fiercebiotech.com/biotech/fdas-pazdur-have-your-cancer-confirmatory-trial-underway-accelerated-approval-expect

[Noteable]

Pazdur's 2022 comments have been superceded by the FDA's move towards biomarkers and surrogate endpoints in early Phase1/2 clinical trials to facilitate quick Accelerated Approvals for orphan and rare diseases, like advanced/metastatic pancreatic cancer (mPDAC), that are followed with confirmatory trials, in contrast to drugs to treat common diseases, which are approved once confirmatory

[Noteable]

The FDA doesn’t “have to get to 100% certainty between an accelerated approval endpoint and a clinical endpoint," Marks added. “If that were the case, there wouldn't be a difference, then we wouldn't have accelerated approval,” he said. The agency can mitigate uncertainty by “using science to the fullest extent," according to Marks—be it available animal data or strong human

[inthno]

Hello notable and I agree with you and have become better informed. My question and you may know is how many people do you think a company would need to have in a trial to possibly get an AA. If.they were going by numbers one would think that the mbc would have a.better chance. Also one would think they would have had an answer by now if.they had applied. I guess we shall know soon enough.

[Noteable]

Re-read this ... " the FDA's move towards biomarkers and surrogate endpoints in early Phase1/2 clinical trials to facilitate quick Accelerated Approvals for orphan and rare diseases, like advanced/metastatic pancreatic cancer (mPDAC), that are followed with confirmatory trials, in contrast to drugs to treat common diseases, which are approved once confirmatory trials are underway

[13X2413]

Ok. Thanks for clarifying. I must admit, I'm turning a little more positive these days. 

[Buckhenry]

2023 will go down as the year of regurgitation. With no news on the horizon I expect the blind pumpers to regurgitate their regurgitation.  

[Noteable]

In October 2023 ONCY's Phase 1/2 GOBLET study evaluating pelareorep-based combination therapy in patients with pancreatic ductal adenocarcinoma reported positive and consistent data on pelareorep, including an impressive overall response rate, 7.2 months of median progression-free survival, interim median overall survival of 10.6 months, and expansion of both pre-existing and new T

[Noteable]

• T-cell receptor (TCR) interaction with major histocompatibility complex–antigen complexes leads to antitumour responses. • TCR sequencing analysis allows characterisation of T cells that recognise tumour neoantigens. • T-cell clonal revival and clonal replacement potentially underpin immunotherapy responses. https://www.ncbi.nlm.nih.gov/pmc/articles

[Noteable]

“The data from [ the Goblet Phase 2 PDAC Cohort study showed ] a correlation between the expansion of TIL-specific clones and tumor response, which provides compelling support for the use of pelareorep-based therapies in immunologically “cold” tumors. In particular, these data, along with the impressive clinical results, support the ability of pelareorep-checkpoint inhibitor

[Noteable]

CEACAM6 and IFITM3 as potential biomarkers for pelareorep in pancreatic adenocarcinoma (PDAC). Conclusions: High CEACAM6 and IFITM3 play a role in P viral infectivity across multiple pancreatic cell lines, confirming results obtained in translational datasets. https://ascopubs.org/doi/abs/10.1200/JCO.2024.42.3_suppl.684?af=R